Testosterone (T) supplementation increases fat-free mass (FFM) and muscle size.
Introduction
Testosterone supplementation increases fat-free mass and muscle size in healthy, hypogonadal men (5, 8, 18, 29, 35, 36) , HIV-infected men with low testosterone levels (3, 6, 15, 16) , and older men with low testosterone levels (19, 30, 31, 33). However, there are striking qualitative and quantitative differences in this anabolic response to testosterone administration among the various studies. Of the six, placebo-controlled, clinical trials evaluating testosterone administration in HIV-infected men, two (11, 12) reported no significant difference in the change in fat-free mass between the placebo-and testosterone-treated men. Among the studies that did demonstrate significant gains in lean body mass following androgen administration, the magnitude of increase varied considerably (3, 6, 15, 16) . In one study (3) in which HIV-infected men with low testosterone levels were treated with placebo or testosterone patches, the mean gain in lean body mass in the testosterone-treated men was 1.4 kg, while in another study (6) , 100-mg testosterone enanthate weekly was associated with a larger (mean 2.9 kg) gain in lean body mass.
Studies of testosterone supplementation in older men have also demonstrated similar variability in results (19-21, 30, 31, 33). While Sih et al. (21) reported no significant gains in lean body mass during testosterone administration, others (30, 31) found greater gains in older men treated with testosterone than in those treated with placebo. These data are similar to anecdotal reports that athletes using androgenic steroids differ significantly in their anabolic response to these agents. We do not know whether these varying responses in HIV-infected and older men in different studies are due to differences in testosterone dose, baseline characteristics of the subjects, or methods of body composition assessment.
We recently completed a clinical trial to determine the effects of graded doses of testosterone on several androgen-dependent processes. In the current investigation, we used multiple linear regression analyses to identify those baseline variables that could best explain the variability in anabolic response to testosterone supplementation. We explored statistical models to best explain the dose-response relationship between serum testosterone and change in various androgen-dependent processes over a range of serum testosterone concentrations from sub to supraphysiological levels (7) . We further examined whether, in addition to the testosterone dose administered, any single baseline variable or combination of baseline variables including age, measures of body composition, serum hormone and growth factor concentrations, skeletal muscle function and morphometry or polymorphisms in androgen receptor gene could explain the variability in anabolic response. We operationally defined anabolic response as the change in lean body mass measured by DEXA scan, a change in appendicular (arm plus leg) lean body mass, measured by DEXA scan, and a change in thigh muscle volume, measured by magnetic resonance imaging (MRI). A second objective of this study was to develop equations that could be used to predict the change in fat-free mass and muscle volume during testosterone administration.
We treated healthy young, eugonadal men with a long-acting gonadotropin-releasing hormone (GnRH) agonist plus one of five doses (25, 50, 125, 300 or 600mg/week) of testosterone enanthate (TE). The study design and the main findings of this study have been published elsewhere (19). Using this model of combined GnRH plus TE administration, we were able to suppress endogenous testosterone production resulting in more homogeneous levels of circulating testosterone within each of the 5 dose groups and more diverse testosterone concentrations, ranging from subphysiologic to supraphysiologic levels, among the 5 groups.
METHODS
Study Design. The protocol for this double blind, randomized, testosterone dose-response study was approved by the institutional review boards of Charles Drew University and the Research and Education Institute at Harbor-UCLA Medical Center. The entire trial consisted of a 4-week control period for baseline studies, followed by 20-weeks of treatment with a long acting GnRH agonist plus TE and 16-weeks of recovery. Details of the study design have been published (7, 22, 24) .
Participants. Participants included eugondal men, 18-35 years of age, who had not used anabolic agents, exercise trained or participated in competitive athletics for 12 months prior to the study.
Randomization. Sixty-one eligible, healthy young men were randomized to receive one of five weekly doses (25, 50, 125, 300 or 600 mg/week) of testosterone enanthate in combination with monthly injections of a long acting GnRH agonist. To ensure compliance, participants received their injections in the GCRC.
Diet and Exercise. Diet and exercise stimulus were standardized two weeks before and throughout the treatment period. Caloric and protein intake were maintained at 36 Kcal/kg/day and 1.2 g/kg/day, respectively. Adherence was monitored using 24-hour food-recall and 3-day food records every 4 weeks. Participants were asked not to engage in strength training or moderate to intense aerobic exercise throughout the study.
Outcome Measures. The independent variables examined included testosterone dose, age, measures of body composition (weight, height, body mass index, total body fat and lean mass), leg muscle performance (leg press strength, power and local muscular endurance), skeletal muscle morphometry (mean fiber area and fiber type from biopsies of vastus lateralis); serum hormone concentrations (total and free testosterone concentrations, sex hormone binding globulin: SHBG, luteinizing hormone (LH), LH to testosterone (LH/T) concentration ratio, log [LH/T] ratio and follicle-stimulating hormone: FSH); concentrations of insulin-like growth factor-I (IGF-I) and its major binding protein IGFBP-3; lipid profile including high (HDL) and low density (LDL) lipoprotein cholesterol concentrations; hematocrit and hemoglobin; prostate specific androgen (PSA) levels; and lengths of the polyglutamine (CAG) and polyglycine (GGC) trinucleotide tracts in exon 1 of the androgen receptor gene. These measures have been shown previously to be androgen responsive. We used LH to testosterone ratio as a marker of the feed-back and feedforward relationship between the gonadotrope and the Leydig cell. Variations in the lengths of the CAG and GGC trinucleotide tracts have been reported to correlate inversely with the variation in the transcriptional activity of the androgen receptor protein, and the risk of prostate cancer and infertility in men (13, 32). We examined the extent to which the variation in biologic response to testosterone could be explained on the basis of polymorphisms in the length of these tracts.
INDEPENDENT VARIABLES EXPLORED:
All independent variables were measured at baseline, within 2 weeks prior to initiating treatment.
Whole Body and Appendicular Fat and Lean Body Mass. Total body fat and lean mass were measured by DEXA scanning (Hologic QDR 4500A, Waltham, MA). Appendicular skeletal muscle and fat masses were determined by adding the bilateral arm and leg lean and fat masses, respectively (17) .
Leg Muscle Performance. Unilateral leg press strength was measured as the maximum amount of weight that could be lifted once (1 repetition maximum: 1RM) on a Keiser leg press device.
Measures were repeated twice (2-5 days apart) and a 3rd time (if the difference between the first 2 days exceeded 5%). Muscular endurance was measured as the maximum number of repetitions that could be performed using a load equal to 80% of each individual's 1RM. Leg power was measured as the maximum rate of force produced (watts) using a Nottingham leg extension rig.
Vastus Lateralis Muscle Biopsies. Percutaneous needle biopsies of the right vastus lateralis muscle were obtained using the Bergstrom method. Muscle fibers were identified as either type I or type II fibers by immunohistochemical staining as previously described (24). At least 500 muscle fibers were counted for each biopsy specimen. The relative abundance of type I and II fibers was expressed as a percent of the total number of fibers counted. The cross-sectional area of the muscle fibers (A) was determined by point counting (1, 23) . A minimum of 150 type II fibers and 100 type I fibers were analyzed in each biopsy specimen.
Hormonal Assays. Serum total testosterone and estradiol concentrations were measured by immunoassays (3-7), free testosterone by equilibrium dialysis (25), LH, SHBG and PSA by immunoradiometric assays (4-7), and IGF-I was measured after acid-ethanol extraction. Serum IGF-binding protein-3 (IGFBP-3) was measured by a specific radioimmunoassay (RIA) that does not cross-react with other currently known IGFBPs. The sensitivities, and intra-and inter-assay coefficients of variation were as follows: total testosterone, 0.6 ng/dL, 8.2% and 13.2%; free testosterone, 0.22 pg/mL, 4.2%, and 12.3%; estradiol, 2.5 pg/ml, 6.5% and 12.4%; LH, 0.05 U/L; 10.7%, and 13.0%; SHBG, 6.25 nmol/L, 4% and 6%; PSA 0.01 ng/mL, 5.0% and 6.4%; and IGF-I, 80 ng/mL, 4% and 6%, respectively (3, 6, 18, 29) .
Lengths of CAG and GGC Repeats. In a subset of participants (n = 38), genomic DNA was isolated from the muscle biopsies using TRIZOL reagent (GIBCO BRL). PCR amplifications were performed in a final volume of 25 µl reaction mix containing 50-100 ng genomic DNA, 25 pmol primers, dNTPs and AmpliTaq polymerase (Perkin Elmer). For the CAG repeat analysis we used two pairs of oligonucleotide primers. The first set was 5'-GCGCGAAGTGATCCAGAAC-3' and 5'-CTTGGGGAGAACCATCCTC-3'. The primer previously described by Edwards (13) was modified slightly based on a computer search (website: www-genome.wi.mit.edu/primer3). analyzed by sequencing using T7 and SP6 sequencing primers.
Primers for GGC repeat analyses were designed as described above. The optimal annealing conditions were pre-tested using RoboCycler Gradient Temperature Cycler between 57 and 68°C using three different primer sets. The best amplification was obtained by using primers 5'-CTCATCCTGGCACACTCTCT-3' and 5'-CAGGGTACCACACATCAGGT-3', and annealing temperature of 63°C. The 25 µl reaction mix consisted of 50-100 ng genomic DNA, 10x buffer, Q solution, dNTPs and Taq polymerase (QIAGEN, Taq PCR Core Kit). The 5' primer was labeled with 6-FAM dye, and the expected 220 bp PCR product was analyzed by STR method. To validate the procedure and verify that the correct product was being amplified, the PCR products obtained from amplification of CAG and GGC-containing segments were subcloned and sequenced.
DEPENDENT VARIABLES:
Whole body DEXA and MRI scans of the thigh were obtained at baseline and after 20 weeks of treatment. Anabolic response was operationally defined as change in: 1. total LBM measured by DEXA scan; 2. appendicular LBM measured by DEXA scan; and 3. thigh muscle volume measured by MRI. Change in each of these 3 variables was calculated as the week 20 value minus baseline value. These dependent variables were selected because they are known to be androgen-responsive and can be measured with high degree of precision and accuracy.
Thigh Muscle Volume. Thigh muscle volume was measured from MRI scans of the thigh, by using a Signa Horizon LX Scanner (General Electric Medical Systems, Milwaukee, WI) at baseline and after 20 weeks of treatment, as previously described (19). Cross-sectional MRI scans of the thigh were obtained with the first slice taken at the inferior border of the lateral femoral condyle. A total of 17 slices were obtained (10 mm thick, 15 mm apart). Thigh volumes were determined for 3 sequential transverse slices of the right thigh, including the slice with the largest cross-sectional area on axial imaging plus the slice immediately above and below, for each subject using commercially available software (General Electric Volume Analysis Software, AW Version 3.1, Milwaukee, WI). Accuracy of the volume analysis software was determined by scanning and analyzing a phantom cylinder of known dimensions. Duplicate manual tracings were drawn around the outermost edge of the entire thigh (total thigh), the skeletal musculature (to subtract out subcutaneous fat) and the femur (to subtract out femoral bone areas). The quadriceps musculature was measured by manually tracing around the vastus lateralis, vastus medialis, rectus femoris and sartorius muscles. All analyses were done by the same investigator, in a blinded fashion.
Accuracy of the volume analysis was verified by scanning a phantom cylinder of known dimensions.
Statistical Analyses and Model Development. SigmaStat (SPSS Science version 2.03, Chicago, Illinois) and Statistical Analysis Systems (SAS version 8.1,SAS Institute Inc., Cary, NC) were used for all statistical analyses. Correlations were examined using the Pearson product-moment correlation coefficient. Testosterone dose and all baseline variables were screened, using univariate regression analyses, to identify those variables to be further examined using multiple regression models. Only variables that were correlated, using a conservative significance level of p < 0.3, with the dependent variables (change in total LBM, change in appendicular LBM or change in thigh muscle volume) were included in subsequent multiple regression analyses. The following baseline variables met this criteria and were examined further in multiple regression analysis: testosterone dose, age, BMI, total and free testosterone concentrations, log LH/T ratio, SHBG and FSH concentrations, triglycerides, VLDL-C, Apo-CIII, leg press strength and local muscular endurance, PSA, hemoglobin, and lengths of CAG and GGC repeats. Best subset regression analyses were used to identify the model that best predicted the change in each of the dependent variables. The multiple regression model that maximized R-square (the square of the multiple regression correlation coefficient) and optimized Mallow's C p statistic for each of the dependent variables was selected. The level of significance was set at p < 0.05.
To ensure that possible collinearity of independent variables did not affect the analysis, the method of ridge regression was employed to reassess each model. The prediction models that emerged from the multivariate analyses were cross-validated in seventeen randomly selected subsets of data in which a small number of randomly selected subjects (<25%) were left out.
RESULTS
Participant Characteristics. Details of the study design have been published (7) . Fifty-four of the 61 men who were randomized completed the entire study. One man discontinued treatment because of acne; the other six withdrew because of an inability to meet the demands of the protocol. Eleven were randomized to receive TE 25 mg/week (group 1), eight to receive TE 50 mg/week (group 2), twelve to receive TE 125 mg/week (group 3), ten to receive TE 300 mg/week (group 3), and thirteen to receive TE 600 mg/week (group 5). There were no significant differences among the 5 treatment groups with respect to baseline characteristics (Table 1) .
Compliance with GnRH agonist injections was 100%. Only one individual in the 125-mg group missed one testosterone injection.
Hormone Levels. As previously reported (7), minimum serum total (r = 0.82, p < 0.0001) and free (r = 0.71, p < 0.0001) testosterone levels, measured during week 20, one week following the previous testosterone injection, were linearly correlated with testosterone dose. Estradiol levels paralleled those of total testosterone. Serum LH levels were suppressed across all 5 groups.
Development of Univariate Regression Models
We tested linear, log linear and growth models to describe the relationship between steady state testosterone concentrations and change in fat-free mass and muscle volume. The linear and log linear models provided the best fit for these data. Since the linear model provided as good a fit as the log linear model, correlations between testosterone dose or concentrations and change in fat-free mass and muscle volume are derived using the linear regression model.
We examined the change in total body and appendicular fat-free mass as a function of serum total and free testosterone levels during treatment. There was a strong linear relationship between TE dose and change in total body fat-free mass (r = 0.81, p < 0.0001; Figure 1 panel A).
The nadir serum total (r = 0.62, p < 0.0001) and free (r = 0.59, p < 0.0001) testosterone concentrations during treatment were also linearly related to change in total body fat-free mass.
Changes in appendicular LBM were highly correlated with testosterone dose (r = 0.79, p < 0.0001; Similarly, steady state free testosterone levels accounted for 35% (p<0.001) and 30% (p<0.001) of the variation in total and appendicular FFM responses, respectively (Table 2a through 
Multivariate Prediction Model Based on Subject Characteristics and Testosterone Dose
i. Predicting change in whole body fat-free mass (DEXA). In the multivariate analysis, testosterone dose alone explained 64% of the variance of change in whole body FFM measured by DEXA. The best 3 variable model that explained more than 67% of the variation in anabolic response included testosterone dose, age and baseline levels of PSA ( Table 3) . The model was developed such that, change in total body FFM = β o + β 1 (testosterone dose) + β 2 (age) + β 3 (baseline PSA). The equation for the preferred model was: change in total body FFM (kg) = -3.242 + 0.015 (TE dose in mg/week) + 0.189 (age in years) + 1.873 (PSA in ng/ml) ( Table 3) .
When testosterone dose was excluded from the multiple linear regression analysis, only 17% of the variability in change in whole body FFM could be explained using a 3 variable model that included baseline measures of triglycerides, leg press endurance and hemoglobin ( Table 4) .
ii. Predicting change in appendicular fat-free mass (DEXA). The best model that explained about 64% of the variation in change in appendicular fat-free mass was a 3 variable model that included testosterone dose, PSA level at baseline, and leg press strength ( Table 3 ). The equation for the preferred model was: change in appendicular fat-free mass (kg) = -1.732 + 0.0078 (TE dose in mg/week) + 0.861 (PSA in ng/ml) + 0.0014 (leg press in kg) ( Table 3) . When testosterone dose was excluded from the multiple linear regression analysis, only 16% of the variability in change in appendicular FFM could be explained using a 3 variable model that included baseline measures of VLDL-C, hemoglobin and leg press endurance ( Table 4) .
iii. Predicting change in thigh muscle volume (MRI).
In the multivariate analysis, testosterone dose alone explained 64% of the variance. None of the other baseline subject characteristics in of themselves were good predictors of the change in muscle volume. The best 3 variable model that explained 70% of the variation in the change in muscle volume included testosterone dose, the log [LH/T] concentration ratio at baseline, and age ( Table 3 
Ridge Analysis for the Effects of Multi-collinearity
Regression analyses can produce estimates with large mean square error when predictor variables are multicollinear. Ridge regression can reduce the impact of multicollinearity in ordinary least squares regressions. As some of the predictor variables in each of the prediction models were correlated, we performed ridge regression analyses to evaluate the effects of multicollinearity. Ridge regression results were similar to those of the best subset regression analyses with no appreciable change in mean square error for any of the three prediction models developed.
Cross-validation of the Models
The prediction models that emerged from the multivariate analyses were cross-validated in seventeen randomly selected subsets of data in which a small number of randomly selected subjects (< 25%) were left out of the analysis for each run. Best subset regression analysis, to maximize R square, was run on these 17 subsets of data. The frequency with which each of the 3 variable models occurred on the 17 runs was used to confirm the selection of the best predictor variables in each of the three prediction models developed. In all cases testosterone dose was a significant predictor. For change in total body FFM, in addition to testosterone dose, age also appeared in almost all of the cross-validation runs. For change in appendicular FFM, testosterone dose and the PSA level were significant predictors for the majority of runs, while the baseline leg press strength appeared less frequently. Finally for the change in thigh muscle volume, testosterone dose, and log (LH/T) appeared in a substantial number of runs, as did age to a lesser extent.
DISCUSSION
The mean change in whole body fat-free mass, appendicular FFM and muscle volume were strongly correlated with testosterone dose and steady state testosterone concentrations during the period of exogenous testosterone administration. Testosterone dose was the best predictor of anabolic response to testosterone administration, and accounted for a major part (61-65%) of the variance in anabolic response. A regression equation that takes into account testosterone dose can largely predict the anabolic response, as measured by change in whole body FFM, appendicular FFM or thigh muscle volume.
Serum total and free testosterone concentrations are a function of the administered testosterone dose, the absorption kinetics, and plasma clearance. Therefore it is not surprising that steady state total and free testosterone concentrations during treatment explained 32-39% of the variance in change in anabolic response. In spite of the high degree of correlation between testosterone dose or testosterone concentrations and the anabolic response, considerable heterogeneity existed when within-dose group responses were considered. Regardless of the dependent variable used to evaluate androgen responsiveness (change in whole body FFM, appendicular FFM or thigh muscle volume), testosterone dose explained 61 to 64% of the variance in response. The addition of age and baseline PSA to the model for change in total body FFM;
baseline PSA and leg press strength to the model for change in appendicular LBM; and log LH/T ratio and age to the model for change in thigh muscle volume accounted for only an additional 3-5% of the variance in anabolic response. When testosterone dose was excluded from the independent variables assessed, only 10-18% of the variance in anabolic response could be explained. Furthermore, in cross-validation subset analyses, only testosterone dose and age were consistent predictors of anabolic response. It is possible that one or more additional variables, including combinations of genetic polymorphisms, might have small effects on the natural variation in androgen responsiveness. Studies with sample size of 1,000-2,000 men would be needed to detect the small contribution of these polymorphisms to the variation in response.
Our data were derived in healthy young men; we do not know whether similar doseresponse relationships exist in older men, or in men with chronic illness. It is also unknown whether women have different androgen responsiveness than men. The study population was ethnically heterogeneous; it is possible that individuals of different ethno-genetic background might respond differently to androgen administration; our study was not designed or powered to address that issue. These empirically-derived prediction equations need to be tested in other populations and prospectively in another study in this subject population.
One disadvantage of using testosterone esters is that testosterone levels vary in temporal relation to the time of testosterone administration (28). Currently, it is only with the use of testosterone esters that one can achieve a wide range of circulating testosterone concentrations, particularly very high concentrations. The testosterone concentrations reported here are nadir concentrations; total and free testosterone levels at other time points must have been higher. We used nadir testosterone concentrations only as a marker of "androgen exposure". We did not measure peak or average testosterone concentrations; it is possible that peak or average testosterone concentrations achieved during the interval after each testosterone enanthate injection might be better predictors of the outcomes than nadir testosterone concentrations.
Baseline body composition, muscle size, and muscle morphology did not affect subsequent response to testosterone administration. It is possible that factors that determine skeletal muscle mass and fiber composition are different from those that determine the magnitude of anabolic response to androgen. We only examined the influence of CAG and GGC repeat lengths in the androgen receptor gene; it is possible that polymorphisms in other genetic determinants of skeletal muscle mass, such as myostatin, angiotensin converting enzyme, IGF-I receptor, GH receptor or other genes might explain some of the variance in anabolic response to testosterone.
The transcriptional activity of the androgen receptor protein has been linked to the length of two polymorphic trinucleotide tracts in exon 1: the CAG repeat, which codes for a polyglutamine tract; and the GGC repeat, which codes for a polyglycine tract (2, 9, 10, 26, 27).
The length of the CAG repeat is usually between 8 and 35 in healthy, young men, while the number of GGC repeats varies from 10 to 30. Individuals with >40 CAG repeats suffer from a neurological disorder, spinobulbar muscular dystrophy. The changes in the length of GGC are not as well characterized, as those in CAG repeat, but deletions of the GGC repeat reduce the transcriptional activity of the androgen receptor by one-third (14) . Our data did not reveal a major effect of either polyglutamine or polyglycine tract length on the change in fat-free mass or muscle volume in response to testosterone administration. Conflicting data exist on the relationship between polymorphisms in androgen receptor gene and infertility, prostate cancer risk, cardiovascular risk, and bone density (2, 9, 10, 26, 27, 34, 37) likely due to small effect size and suboptimal sample size of these studies.
Based on these prediction models, we considered the possibility that the differences in testosterone dose and concentrations might account for the differences in anabolic response observed in HIV-infected men and in older men. Indeed, we observed greater gains in fat-free mass in HIV-infected men treated with testosterone enanthate injections, 100 mg weekly (6), than those receiving testosterone replacement by a 5-mg testosterone patch (12). Because 100-mg weekly dose of testosterone enanthate delivers a larger amount of testosterone than that delivered by the 5-mg patch, our model would predict greater accretion of lean tissue with this higher dose.
Similarly, most studies of testosterone supplementation in older men used relatively small doses of testosterone that raised serum testosterone concentrations into the lower end of the normal male range; therefore, it is not surprising that the increments in fat-free mass and muscle strength in these studies have been modest. Our prediction model suggests that increasing testosterone concentrations into the higher end of the normal male range would be associated with greater gains in muscle mass and likely muscle strength; the safety and effectiveness of such an approach should be tested in prospective clinical trials.
Our analysis shows that the biologic response to exogenously administered testosterone can be largely predicted by taking into account the administered dose and age; PSA level, log 10 (LH/T) and leg press strength only marginally improve the model. Because a large part of the variance is accounted for by these variables that can be easily measured, it would be possible to predict the change in lean body mass and muscle size. The regression equations developed from these data in healthy young men should be tested prospectively in other populations to establish their validity and generalizability. Legend. Data represent baseline mean ±SD values for the 54 participants who participated in the study. Legend: A linear regression model was used to investigate how much of the variance in anabolic response, change in appendicular fat-free mass measured by DEXA (kg), could be explained by free testosterone concentrations during treatment. Serum free testosterone levels were measured after 16 weeks of TE treatment at nadir, one week after the previous injection. R-square = 0.30, Fstatistic=22.21, p < 0.001. Table 4 . Results of the best subset multiple regression to assess determinants of androgen responsiveness defined as change in fat-free mass and thigh muscle volume when testosterone dose was excluded. 
